Abstract Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved > or =1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.

Aged, Aged, 80 and over, Antibodies, Monoclonal/ therapeutic use, Antibodies/ metabolism, Antineoplastic Agents/ therapeutic use, Female, Hu Paraneoplastic Encephalomyelitis Antigens/immunology, Humans, Male, Middle Aged, Nerve Tissue Proteins/immunology, Paraneoplastic Syndromes, Nervous System/ drug therapy/ immunology, Treatment Outcome
dx.doi.org/10.1007/s00415-005-0882-0, hdl.handle.net/1765/21818
Journal of Neurology: official journal of the European Neurological Society
Erasmus MC: University Medical Center Rotterdam

Shams'ili, S, de Beukelaar, J.W.K, Gratama, J.W, Hooijkaas, H, van den Bent, M.J, van 't Veer, M.B, & Sillevis Smitt, P.A.E. (2006). An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Journal of Neurology: official journal of the European Neurological Society, 253(1), 16–20. doi:10.1007/s00415-005-0882-0